Sun Pharmaceutical Industries Ltd management interview: Sun Pharma Q2: ₹1,269 Crore Exceptional Loss Hits PAT; CFO Explains Organon Impact | Business News
ET Now, 2026-11-02. Video: https://www.youtube.com/watch?v=fNW4QLy6CIU
- Margin outlook: Sun Pharma does not provide quarterly or full-year margin guidance. Management said gross margins have been good and marginally increased even after excluding lenalidomide.
- Ilumya sales: Sales were soft due to external and internal factors; the company has strengthened its sales force and expects the newly approved PSA indication to augment sales. Management declined to give a specific revenue contribution.
- Organon synergies: The acquisition is expected to be completed in early Q4 of FY27. Synergies across the value chain are expected to materialize over 2 to 3 years, reaching close to $350 million.
- India business: India formulations grew 17.5% almost year on year, led by volume growth, pricing and new products. Semaglutide has made Sun Pharma the number 2 player in the generic segment of injectables.
- FY27 outlook: Sun Pharma is maintaining its high single-digit revenue growth guidance, despite 11% growth in the first half; management said it does not revise guidance during the year and continues to look for upside. The discussion also cited an exceptional loss of about ₹1,269 crore related to the Organon acquisition.